Roche Stops Work on Olesoxime After Disappointing Long-term Results in Phase 2 Trial
Roche has stopped the development of olesoxime, a treatment candidate for spinal muscular atrophy (SMA) following disappointing 18-month results in an ongoing clinical study, the company announced. In a statement shared online through TreatSMA, Roche mentioned the most recent results of the OLEOS Phase 2 trial (…